In a major update published this morning, @acscan.bsky.social now includes our Shield™ blood test in its #ColorectalCancer screening guidelines — recognizing blood-based screening as a new option to help expand access and increase screening participation. More: bit.ly/4uzMULX

Yesterday, we shared our first quarter 2026 financial results, with 48% year-over-year revenue growth driven by strong performance across our Oncology and Screening businesses. More details: bit.ly/4uVYz7R

We’re proud to share the FDA’s approval of Guardant360® CDx as a companion diagnostic for VEPPANU (vepdegestrant) for patients with ER+/HER2- advanced #BreastCancer with ESR1 mutations, marking our third ESR1 companion diagnostic FDA approval. Details: bit.ly/4tJNbLS

Thank you to @guardanthealth.bsky.social for hosting our Q1 meeting! Darya Chudova, Guardant's CTO & BLOODPAC's Scientific co-chair welcomed members and reminded us that BLOODPAC’s mission remains the same: reducing the time it takes for liquid biopsies to impact patient care.

Today, we reported our fourth quarter and full year 2025 financial results, marking a significant close to an exceptional year with 39% year-over-year revenue growth in Q4 driven by strong performance across our Oncology, Screening, and Biopharma and Data business units. Details: bit.ly/46M8AdU

We’re honored to share that the FDA has approved Guardant360® CDx as a companion diagnostic for BRAF V600E–mutant metastatic #ColorectalCancer, helping identify patients who may benefit from BRAFTOVI® (encorafenib)–based treatment. Details: bit.ly/49ODNh8

Together with Merck, we’re advancing the development and global commercialization of new cancer therapies through a multi-year strategic collaboration leveraging our Guardant Infinity™ Smart Platform. More details: bit.ly/4k0Od23

We’re looking forward to joining the healthcare and investment community at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where our management team will present and participate in a live Q&A on Monday, January 12 at 3:45pm PT. More details: bit.ly/3N7tsWf

Onward to 2026, a new year to remain driven by purpose, grounded in science, and focused on what matters most: patients. Here’s to moving forward with clarity, momentum, and continued innovation.

For the fourth year in a row, we’ve been named to @computerworld.com’s #BestPlacesIT list, ranking 18 among midsize organizations for 2026. Truly grateful to our global technology teams for the culture that drives our mission forward. Details: bit.ly/4oOLbyI

Today we announced a collaboration with Trial Library that unites our large-scale genomic data & their AI-powered matching & navigation platform to help more patients, including those in underserved communities, reach the right precision oncology clinical trials. Details: bit.ly/4rQFanR

Introducing FPG 360, one of Italy’s first in-house liquid biopsy testing services at the Policlinico Gemelli in Rome. Powered by our Guardant360® CDx technology, this new service expands access to precision oncology diagnostics & supports both routine care & #ClinicalResearch. Info: bit.ly/44SFOax

We look forward to sharing new data at #SABCS25, where we will present 14 abstracts demonstrating the power of multiomic liquid biopsy testing in predicting outcomes & tailoring treatment for patients with early and metastatic #BreastCancer. Details: bit.ly/49TyQpc

Shield™ is poised to change how the U.S. screens for #ColorectalCancer but outdated guidelines are holding back access. Our Co-CEO AmirAli Talasaz outlines why millions remain unscreened despite the availability of the first FDA-approved blood test for primary CRC screening. Read: bit.ly/4rFXFvl

As MRD testing becomes integral to clinical development, understanding tissue-informed vs. tissue-free approaches is key. Join us on Monday, November 24 at 2PM PT to explore the latest in MRD for #BreastCancer. Register: bit.ly/48kthPa

Colorectal cancer is often silent in its early stages. We can change that by spreading the word about the importance of early detection! 📣 #NoShaveNovember is the perfect time to encourage regular screening among the older adults you serve. Get the facts and help #FightCRC. ⬇️

We’re excited to announce the launch of the Single Namespace Working Group, a 34-member consortium uniting leading technology, healthcare, & research organizations to establish the first open standard for exabyte-scale data interoperability. Details: bit.ly/3JZUU6X

The next evolution of Guardant Reveal® is here. Details: bit.ly/3Xn7AaY

A #NewStudy published in The Journal of Liquid Biopsy validates the effectiveness of our Guardant Reveal® blood test in monitoring chemotherapy response across advanced cancers. Details: bit.ly/4oRkUjB

Real-world evidence continues to build for Shield™: A new study published in Current Medical Research and Opinion found that Shield demonstrates 95% patient adherence for #ColorectalCancer screening among 20,000 patients. Details: bit.ly/3LhRgFY

Tomorrow, our Co-CEO AmirAli Talasaz joins global health leaders at #MIHealthSummit for a panel exploring how we can make health care access more personal, preventive, & proactive. Watch live tomorrow: bit.ly/43UBqHv

We have reported our third quarter 2025 financial results, highlighted by 39% year-over-year revenue growth. Our continued momentum has led us to raise our full-year 2025 revenue guidance to $965–$970 million, representing 31% year-over-year growth. Details: bit.ly/4nBoZaJ

We’re proud to announce a strategic partnership with Zephyr AI to deliver novel, scalable, & actionable insights that support biopharma innovation, reflecting our shared commitment to leveraging AI and multimodal data to advance #CancerResearch and improve #PatientCare.

We're sharing data at #ACG2025, highlighting the critical role of blood-based testing in improving #CancerScreening adherence. Data presentation details: bit.ly/4odIp6K

We’re excited to be at #JADPROLive in National Harbor, Maryland! Stop by Booth #510 to meet our medical affairs team and explore the vital role oncology advanced practitioners play in advancing precision cancer care through molecular testing.

Innovations in cancer diagnostics are transforming the landscape of care. The latest @milkeninstitute.org Institute report explores how liquid biopsies — noninvasive, blood-based tests — can revolutionize #CancerDetection and treatment. Read more: bit.ly/4opJhVy

We’re excited to share our latest data this week at #ESMO25! 📍Visit us at Booth 3021 to learn more. Additional details: bit.ly/4nVIQCu

We’re proud to share that the FDA has approved our Guardant360® CDx test as a companion diagnostic for @elilillyandcompany.bsky.social's Inluriyo™ (imlunestrant) for ESR1-mutated advanced #BreastCancer. More details: investors.guardanthealth.com/press-releas...

We’re proud to be a partner of the World Clinical Biomarkers & Companion Diagnostics Summit next week. Join our plenary session with Jean-Francois Martini to learn how our flexible solutions combined with multimodal real-world data and can streamline your #ClinicalDevelopment program for success.

We are proud to welcome Alex M. Azar II to our board of directors. Secretary Azar brings a unique perspective on the intersection of policy, innovation, and patient access that will help us advance our mission to conquer cancer with data. Details: bit.ly/4gmjZom

Today we’re excited to announce a new partnership with PathGroup to expand access to our Shield™ #BloodTest for early cancer detection. Through PathGroup’s extensive network, Shield will soon be available in more than 250 hospitals and 15,000 physicians across 25 states. Details: bit.ly/4peK392

On Tuesday, our Co-CEO Helmy Eltoukhy will join @wired.com at #WIREDHealth for a featured conversation: “Winning the War on Cancer." Helmy will explore how liquid biopsies are driving earlier detection, faster treatment decisions, & a more personalized patient experience. Info: lnkd.in/e3KvKNsa

This past weekend, we teamed up with the Dolphins Cancer Challenge before the Dolphins took on the Jaguars to connect with fans and share more about Shield™, the blood test that screens for #ColonCancer the more pleasant way. A big #ThankYou to all the fans who joined the conversation with us!

Today we announced that the 1st patient has been enrolled in the the National Cancer Institute's Vanguard Study, evaluating our Shield™ MCD test. The 4-year study will assess the feasibility of using blood-based tests to detect multiple cancers in individuals w/o symptoms. Details: bit.ly/40jXcms

Join us for a live #Webinar on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials. Register today: bit.ly/44kpIa3 📅 Date: July 24 🕘 Time: 9:00am PT

Last week, our co-CEO AmirAli Talasaz took the stage at #AspenIdeasHealth on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, & AI are reshaping the future of care. Watch the session: bit.ly/4kt5yQ0 Photo credit: Leigh Vogel

At #AspenIdeasHealth, our co-CEO AmirAli Talasaz sat down with @drjohntorres.bsky.social to discuss a critical gap in cancer care: screening technologies are advancing, but access isn’t keeping pace.

Exciting news! Our Shield™ blood test has been recognized on @fastcompany.com's 2025 World Changing Ideas list! We're thrilled to be part of this amazing collection of ideas driving meaningful change in the world. Check out the full list here: fastcompany.com/world-changi... #FCWorldChangingIdeas

Today, we’re proud to share that ESMO Open has published results from the LIBERATE study, highlighting Guardant Reveal’s performance in detecting minimal residual disease in early-stage #BreastCancer. Details: bit.ly/43yOanC

We're honored to announce that our Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the @fda.gov. More details: investors.guardanthealth.com/press-releas...

Featured in @nytimes.com: Our Guardant360® CDx test is helping revolutionize #BreastCancer treatment by detecting drug resistance before it shows up on scans—enabling timely treatment changes and improving patient outcomes.

We’re proud to share that the National Comprehensive Cancer Network has included our Shield™ blood test in its updated #ColorectalCancer screening guidelines. Marking a pivotal step forward in expanding #PatientAccess to an innovative, blood-based screening option. Details: bit.ly/3SxrayX

Today we announced results from the Phase III SERENA-6 trial, demonstrating the clinical value of our Guardant360® CDx test in detecting & treating emerging resistance in advanced #BreastCancer ahead of radiological progression. Details: bit.ly/4mJ3kxU

The future of precision oncology is here. Join us at #ASCO25, booth #25077, to discover the pivotal role of liquid biopsy in transforming cancer care and improving patient outcomes.

At #ASCO25 yesterday, we shared results from the largest study to date evaluating ctDNA in #ColonCancer, highlighting the power of our Guardant Reveal™ test to inform critical treatment decisions. More details: bit.ly/4mFFHq1

Join us at #ASCO25 for an exclusive event showcasing how our Guardant Infinity™ platform is propelling patient-centered care into the future. Discover how redefining precision oncology through innovation & advocacy. 📅 Monday, June 2 🕗 8 AM–5 PM 📍 Marriott Marquis Chicago | Astronomy Room

We’re excited to introduce nearly a dozen new applications for our Guardant360® Liquid test, further enhancing its ability to identify biomarkers and subtype cancers from a blood sample. More details: bit.ly/4dwo7AE

We’re looking forward next week's 2025 ASCO Annual Meeting, where we’ll share data from 19+ studies showcasing the critical role of our liquid biopsy tests in cancer screening, therapy selection, & recurrence monitoring. Stop by booth #25077 at #ASCO25 to learn more. Details: bit.ly/4myVcjK

Today we announced the addition of an extensive suite of immunohistochemistry testing to our portfolio of tumor molecular profiling tests, further supporting oncologists in identifying tumor subtypes and matching cancer patients to the most effective targeted therapies. Details: bit.ly/3SM8xr6

Introducing the Guardant Hereditary Cancer test — our germline test designed to identify inherited genetic variants associated with cancer risk across more than 12 tumor types, helping cancer care teams provide optimal patient care. Learn more: bit.ly/4dtyQMv